FDA clears Welch Allyn Protocol's wireless patient monitor:
This article was originally published in Clinica
Executive Summary
Welch Allyn Protocol has received US FDA 510(k) clearance to market its Micropaq wireless ambulatory patient monitor. The device, developed principally for cardiac care, monitors ECG, heart rate and pulse oximetry. It is compact and wearable, weighing under a pound. The product can be connected wirelessly to the Beaverton, Oregon company's Acuity central workstation and its FlexNet network, which provide vital signs data and patient information between any locations via secure internet access. The device can also be used in applications outside cardiac care because it provides an LCD of vital sign data and can operate outside of the wireless network.
You may also be interested in...
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion
Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.